Pneumococcal Disease News and Research

RSS
Pneumococcal disease describes a group of illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This bacterial pathogen, which affects both children and adults, is a major cause of death and illness worldwide. In fact, according to the World Health Organization (WHO), pneumococcal disease is the number one vaccine-preventable cause of death in children younger than 5 years of age worldwide.
New NPS Direct article reveals that vaccinations fight against antibiotic resistance

New NPS Direct article reveals that vaccinations fight against antibiotic resistance

Griffith University launches new online scholarly journal to fight against pneumonia

Griffith University launches new online scholarly journal to fight against pneumonia

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

European Commission approves updated label of Prevenar 13 for high risk pneumococcal disease

Urinary pneumococcal antigen testing ‘useful in children’

Urinary pneumococcal antigen testing ‘useful in children’

Inhaled corticosteroids increase pneumonia risk in asthma

Inhaled corticosteroids increase pneumonia risk in asthma

Study finds similar antibody levels among 4 PCV13 immunization schedules

Study finds similar antibody levels among 4 PCV13 immunization schedules

Immunization in developing countries: an interview with Dr. Jos Vandelaer, Chief of Immunization for UNICEF

Immunization in developing countries: an interview with Dr. Jos Vandelaer, Chief of Immunization for UNICEF

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer's Prevenar 13 receives European approval to include adults for prevention of invasive disease

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

Pneumococcal vaccine pre-clinical development supported by £0.2 million award from Biomedical Catalyst

Pneumococcal vaccine pre-clinical development supported by £0.2 million award from Biomedical Catalyst

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Results from Pfizer’s Prevnar 13 Phase 3 study on HIV

Vaccine prices and availability: an interview with Kate Elder, Vaccines Policy Advisor for Médecins Sans Frontières's Access Campaign

Vaccine prices and availability: an interview with Kate Elder, Vaccines Policy Advisor for Médecins Sans Frontières's Access Campaign

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

High vaccine prices ignored by ‘Decade of Vaccines’ blueprint

High vaccine prices ignored by ‘Decade of Vaccines’ blueprint

Madagascar faces challenges in vaccinating children

Madagascar faces challenges in vaccinating children

Patients with COPD more likely to develop serious bacterial infections

Patients with COPD more likely to develop serious bacterial infections

EC approves Pfizer’s Prevenar 13 to prevent pneumococcal disease

EC approves Pfizer’s Prevenar 13 to prevent pneumococcal disease

Pneumococcal disease risk increased in mental health patients

Pneumococcal disease risk increased in mental health patients

Dropping of cold chain requirement for meningitis vaccine will improve access, IRIN reports

Dropping of cold chain requirement for meningitis vaccine will improve access, IRIN reports